PerkinElmer paid $38 million to buy Shanghai Haoyuan Biotech Co., a company that has developed four SFDA-approved infectious disease diagnostic tests. The owners of Haoyuan may also receive future payments based on revenues hitting targets. The four assays, which test for hepatitis B, hepatitis C and HIV, are intended for use by blood banks and clinical labs. More details.... Stock Symbol: (NYSE: PKI) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});